Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.
The Company’s three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients; and INGREZZA™, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette Syndrome.
Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine’s chemists, pharmacologists, and biologists strive to create new solutions to unmet medical problems.
TypePublic
HQSan Diego, US
Founded1992
Size (employees)400 (est)
Websiteneurocrine.com
Neurocrine Biosciences was founded in 1992 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Neurocrine Biosciences

Kevin Gorman

Kevin Gorman

CEO
Tim Coughlin

Tim Coughlin

CFO
David-Alexandre Gros

David-Alexandre Gros

President and COO
Eric Benevich

Eric Benevich

Chief Commercial Officer
Julie Cooke

Julie Cooke

Chief People Officer
Show more

Neurocrine Biosciences Office Locations

Neurocrine Biosciences has an office in San Diego
San Diego, US (HQ)
12780 El Camino Real
Show all (1)
Report incorrect company information

Neurocrine Biosciences Financials and Metrics

Neurocrine Biosciences Revenue

Neurocrine Biosciences's revenue was reported to be $15 m in FY, 2016 which is a 24.1% decrease from the previous period.
USD

Revenue (Q2, 2018)

168.0m

Gross profit (Q2, 2018)

166.2m

Gross profit margin (Q2, 2018), %

98.9%

Net income (Q2, 2018)

(47.7m)

EBIT (Q2, 2018)

(39.3m)

Market capitalization (15-Oct-2018)

10.0b

Closing stock price (15-Oct-2018)

110.1

Cash (30-Jun-2018)

166.4m
Neurocrine Biosciences's current market capitalization is $10 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.9m19.8m15.0m

Revenue growth, %

(100%)(24%)

General and administrative expense

13.3m18.0m32.5m68.1m

R&D expense

39.2m46.4m81.5m94.3m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Revenue

19.8m15.0m71.1m168.0m

Cost of goods sold

950.0k1.8m

Gross profit

70.1m166.2m

Gross profit Margin, %

99%99%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

44.8m31.0m74.2m83.3m

Current Assets

148.5m198.2m384.1m310.4m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Cash

37.4m29.0m170.3m132.1m66.4m115.3m86.2m99.8m64.1m175.3m166.4m

Accounts Receivable

44.6m42.6m

Current Assets

197.6m183.9m405.0m389.4m382.8m401.0m392.0m357.9m239.5m513.7m567.7m

PP&E

2.2m2.3m2.5m2.8m2.9m3.9m5.8m6.2m7.1m11.8m18.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(46.1m)(60.5m)(88.9m)(141.1m)

Depreciation and Amortization

671.0k827.0k1.0m1.5m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(13.4m)(15.9m)(1.2m)(24.0m)(34.4m)(19.3m)(40.3m)(36.9m)(78.3m)(41.8m)(47.7m)

Depreciation and Amortization

786.0k1.7m

Inventories

(3.3m)

Accounts Payable

846.0k900.0k1.3m1.0m1.2m2.1m1.8m1.7m852.0k(7.9m)4.3m
USDY, 2018

Financial Leverage

2.2 x
Show all financial metrics
Report incorrect company information

Neurocrine Biosciences News and Updates

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results

SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, Nov. 5, 2018. Neurocrine will then host a conference call and webcast to discuss its financial ...

Neurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders

SAN DIEGO, Oct. 1, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present new long-term data analyses on INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia...

Neurocrine Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

SAN DIEGO, Sept. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Morgan Stanley 16th Annual Global Healthcare Conference at 8:10 a.m. ET on Wednesday, Sept. 12, 2018, in New York City. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, ...

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders

SAN DIEGO, Aug. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA)...
Report incorrect company information

Neurocrine Biosciences Company Life and Culture

Report incorrect company information